DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. - Wikidata - wikimedia - TriplyDB

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

http://www.wikidata.org/entity/Q34606356

about

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review Profiling the host response to malaria vaccination and malaria challenge Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development Protective immunity to liver-stage malaria Malaria vaccine clinical trials: what's on the horizon The March Toward Malaria Vaccines External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance Molecular mechanisms for enhanced DNA vaccine immunogenicity.Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.The influence of delivery vectors on HIV vaccine efficacy Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Recent advances in recombinant protein-based malaria vaccines.Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01 Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vec Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines.Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.

P2860

Q21034050-AD342A9E-5A17-4CEF-9817-9F91856A1DD6 Q26700078-9B4F6B65-C7A4-42EF-98AA-37568CA123A2 Q26800494-003F6F56-68DA-4DAD-99DE-4E53A6CA0D0D Q27026412-A193909E-D9AA-4CE4-AB57-64FCF41E6BE6 Q27972709-31715227-C499-41B3-802E-FD7A8C0590AE Q28068626-708DCA75-C84B-4C0D-AC27-B23B3008E9A8 Q28083110-5A9E044E-7490-4CD4-B1CA-A17575819B6A Q28084325-C5EA757A-815E-4860-B386-33ABAE73C9D3 Q28538917-C0821888-DA78-4551-BA6C-4F692CE97E86 Q30366743-D9F0B1DF-A15E-4C8F-AE31-C0C2972CC577 Q30857727-1B6198B9-3B86-485C-BAD6-743C4EB5C394 Q33855899-3F9CFD17-3522-42AA-91B2-BBF4066D3957 Q33868760-5A355A48-E5AC-4FB7-8425-56A462F74D38 Q34033882-F330E03D-6F1B-4529-B744-4E17A6BC16B7 Q34077543-281B409A-05F3-4E85-9D96-F25C98B99C33 Q34165879-1B77EBBA-0709-475B-837B-28613B7B6604 Q34170122-D0DB6B01-667A-4E26-A6C7-244D68F2444B Q34260720-7ADA434C-6F81-4249-8698-64D0A9F2EB2F Q34291205-1EB4CA18-0F16-42CF-B2C4-C74499BA48FD Q35021277-D5EBE22C-FD5A-4138-8BD7-091A0B6A6FE7 Q35065923-0D73F79E-E8E9-47BE-AA01-71EAD2F62BA6 Q35163318-1B10E89A-C1B0-4438-907A-38938A450688 Q35871976-9E8EFAF6-F1AD-409D-9938-273DD05F556B Q36003208-1E8951C7-DBCB-4786-9D01-A5CE13B7E567 Q36151198-7678105A-69FB-49A3-A6C1-E5ADBD066E77 Q36225504-5605E057-67DC-40C6-B4CB-00E9EE89FDF9 Q36304234-EFD00944-6962-44B6-9CBF-5C6E25840829 Q36389006-B57DCAC9-96E5-44C6-93C4-43B0A34D5EA7 Q36394177-FA044341-C941-4E55-8FDA-241D9B823CE5 Q36394182-9EE47384-74CC-493D-84F9-070B68A15E44 Q36531046-BEFD59E2-537D-450D-89B0-EF7A8ECB2ABC Q36573064-5D596ADC-6CF3-48FC-BE9B-1E6AEE47C43A Q36785777-77621054-139D-44C9-97DE-745B60CA33A8 Q36871970-3511EB4A-F505-474F-BD24-F674034CC8F4 Q36905568-79A61842-4FD7-432D-BB37-6439666C51FA Q37118222-D7BF5598-C531-46BD-9EAC-EDD35C5916CF Q37123522-F2FE5036-4EC2-497E-8B99-C568363C0703 Q37285734-0E614050-F4DC-46B5-863E-E484FC94A59B Q37361903-B9555CA1-9F4F-43B2-806E-AEE0093C44B3 Q37530505-392E8573-BFD1-4B10-9460-B07E2E749167

P2860

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

http://www.wikidata.org/entity/Q34606356

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@ast

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@en

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@nl

type

label

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@ast

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@en

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@nl

prefLabel

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@ast

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@en

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@nl

P1433

Q34606356-68F4FA07-652D-451C-854C-F2264BE85DAD

P1476

Q34606356-8FE0CEAA-37B0-45EE-8478-AC5EED3492C2

P2093

Q34606356-05344752-0302-4345-8D5B-B8C373BA7137

Q34606356-054E6CD8-1912-444F-9540-D23D89E3078C

Q34606356-0583C7FB-AB8A-4FED-8447-5D07B3B1E71F

Q34606356-13F51E89-A4AF-427A-953D-5B830448EA4E

Q34606356-1ECF33F6-1CC5-452A-91C1-C4CDEC47DC67

Q34606356-2229E742-3C5F-4C63-86AD-FC81908B1B0A

Q34606356-25377407-F602-458C-9CEA-D7CC922193E2

Q34606356-2586D261-AC32-40BF-9CE7-2B0E87AD65E1

Q34606356-391E7541-DB15-4C28-964E-D43CB418A952

Q34606356-479A3F2D-62CD-4BB4-84AB-F35B643229C8

P2860

Q34606356-177FCD5B-2E4D-4761-BFBC-CBE8951541E3

Q34606356-1A3FE553-9E65-45EA-A858-D71F047852E0

Q34606356-2B214F45-23FF-4845-8693-841046F15001

Q34606356-2BC382E4-3454-43D8-9491-314A33A99479

Q34606356-2E1D2FE0-9AE1-4EF7-8CDE-FB5E56003006

Q34606356-320F042D-BDDA-4182-A830-BBEF0C2459F8

Q34606356-334D6021-2AF4-4CFB-BD7E-8CFFCDC6323A

Q34606356-35CE3468-DC37-44E3-B05A-711810620652

Q34606356-40A30946-4AED-44E4-831D-A024AB63F663

Q34606356-42E3717C-ECAF-4B9C-8CB3-C496284B1A2D

P304

Q34606356-92A4D989-271F-48F4-9F13-91F101B951D7

P31

Q34606356-38108B80-2B11-4FD7-BD98-2AA656428DF6

P356

Q34606356-E7F4D8BD-D2F3-4967-80CF-DBE9246A43CA

P407

Q34606356-8B5C99C6-D2DA-4A33-86E4-FADDE4E47A24

P433

Q34606356-1B46A908-5A8F-4A0D-B06A-1E50B625DFF9

P478

Q34606356-1E568A2E-1389-49C4-80A4-47E61E6E12F4

P50

Q34606356-1E80DE7D-12DF-48B5-842F-EFF2B6A6744A

Q34606356-BA97DAC0-F411-4530-9F7F-A0132729C6B1

Q34606356-C277579C-4080-4720-9E8A-63016323981C

Q34606356-F16247AA-3D71-4A64-B0E9-27C1CD333E4F

P577

Q34606356-33C0A93A-D312-415B-B55E-04B018A67FAE

P5875

Q34606356-223B6DF0-161C-4954-9003-7C3CF573633F

P698

Q34606356-A2A509A6-7686-462B-933C-4CCEE1F62B93

P921

Q34606356-6DE36EAA-B716-4107-AA4C-10F93AF46B6D

Q34606356-91579621-E687-4972-A1EE-BC9B70F3B843

Q34606356-A8ED0D56-7717-43A7-8EDA-1B4D0D0CE83C

P932

Q34606356-EE735C20-4642-4FC0-9E12-844E04A9543E

P356

JOURNAL.PONE.0055571

P1433

P1476

DNA prime/Adenovirus boost mal ...... d with cell-mediated immunity.

@en

P2093

Andrea J McCoy

http://www.w3.org/2001/XMLSchema#string

Awalludin Sutamihardja

http://www.w3.org/2001/XMLSchema#string

C Richter King

http://www.w3.org/2001/XMLSchema#string

Carter Diggs

http://www.w3.org/2001/XMLSchema#string

Chloe Wood

http://www.w3.org/2001/XMLSchema#string

Christian F Ockenhouse

http://www.w3.org/2001/XMLSchema#string

Cindy Tamminga

http://www.w3.org/2001/XMLSchema#string

Cornelus C Hermsen

http://www.w3.org/2001/XMLSchema#string

Daniel Carucci

http://www.w3.org/2001/XMLSchema#string

Denise L Doolan

http://www.w3.org/2001/XMLSchema#string

P2860

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies.

Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.

P304

e55571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0055571

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Thomas L. Richie

Elke S Bergmann-Leitner

Robert Sauerwein

P577

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235778401

http://www.w3.org/2001/XMLSchema#string

P698

23457473

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

P932

3573028

http://www.w3.org/2001/XMLSchema#string